We’ve done a lot of an analytics. Sure, there’s always going to be a little disruption anytime you change territories, but I think that’s going to be offset by the ability to optimize and place the incremental effort in targeted fashion that’s going to allow us to see a ramp up, in a really reasonable time frame. And then lastly, we’ve got great learnings in terms of what resonates with the doctors in terms of messaging, et cetera. These reps are actually gonna be able to be trained a little bit more effectively and efficiently than even our first class, if you will, because, they’re going to be able to learn from the experience of the current team. So, we expect them to hit the ground running, be able to make impact, and get up to speed. Like I said, I’m really pleased with the quality of people that we’re looking at.
I think this is going to really strengthen our team and we’re doing all we can to manage any disruption. But I think the plan in place will offset any of that temporary disruption you’d see.
Operator: Thank you. One moment while we queue up our final question. This question comes from Corey Jubinville with Life Sci Capital. Go ahead. Your line is open.
Corey Jubinville: Congrats on the numbers and thanks for taking our question. You mentioned potential seasonality due to ECP practices, holidays, vacations, et cetera. Curious if you have any indication that there might also be seasonality in DB that might dictate sales similar to how there might be seasonality in the incidence or in severity of rosacea or allergies.
Aziz Mottiwala: Yes. It’s a good question, Corey. I think it’s still early to tell sort of market seasonality. What we can look at is other product proxies and that we see the impact of holidays when the doctors being out of the office. I think keeping in mind also that this is a, NRx product. The vast majority of the volume comes from NRx. It’s going to be even more sensitive to those swings when the doctors are out or when people are on vacation. I think in terms of the seasonality of the disease, historically, we haven’t seen anything in the literature and all the work we’ve done prior but that’s probably something we’ll see a year or two into the launch when we’ve got a few more under our belt to see if there’s any additional, seasonality that impacts it.
The only other things I would indicate are typically, we know that Q1 is always a challenging quarter. There’s always headwinds in Q1 and we know that Q4s, tend to be a little bit better as people try to come in and get in before their deductible resets and then people are visiting the doctor a little bit more often. That’s not specific to XDEMVY or damaged blepharitis That’s something we see pretty much across the board.
Corey Jubinville: How should we think about R&D spend moving forward now that the Phase 2 studies for rosacea and Lyme are complete? I know we’re awaiting regulator feedback, but are you thinking about taking either of these programs into a Phase 2b or Phase 3 studies and curious if you could speak on how discussions around potential partnership opportunities have progressed so far?
Jeff Farrow: Hey, Corey. It’s Jeff. Yeah, I think for the R&D, we expect it to be relatively flat throughout the year compared to this quarter. We are still closing down sites and interrogating the data. So, there’s still some definite work that’s going on there. I’ll turn it over to Sesha for further discussion on the plans forward.
Sesha Neervannan: Thanks, Jeff. Great question, Corey. In terms of the pipeline progress, we are tracking really well. As we mentioned previously, we are continuing to do additional analysis on all of our Phase 2 trials. Once we have those analysis, our plan is to go to the agency by end of this year. The progress is, progressing really well. We are collecting all of the data and we’ll be pleased to report any progress as we move forward.
Operator: Thank you. I am showing no further questions at this time. Thank you for your participation in today’s conference. And this does conclude the program. You may now disconnect.
